A Phase 1, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Function.

2023-505180-36-00 Protocol SB2640-CLIN-009 Human pharmacology (Phase I) - Other Ended

Start 21 Sep 2023 · End 19 Dec 2023 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol SB2640-CLIN-009

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 48
Countries 1
Sites 1

Impaired Hepatic Function The study will enroll as following: · Group 1 (N up to 24) – Normal hepatic function (healthy subjects) · Group 2 (N 6 to 8) – Mild hepatic impairment (Child-Pugh A - a score of 5 to 6) · Group 3 (N 6 to 8) – Moderate hepatic impairment (Child-Pugh B a score of 7 to 9) · Group 4 (N 6 to 8) – Severe hepatic impairment (Child-Pugh C a score of 10 to 15) Healthy volunteers with normal hepatic function.

Key facts

Sponsor
Sagimet Biosciences Inc.
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
21 Sep 2023 → 19 Dec 2023
Decision date (initial)
2023-08-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Impaired Hepatic Function The study will enroll as following: · Group 1 (N up to 24) – Normal hepatic function (healthy subjects) · Group 2 (N 6 to 8) – Mild hepatic impairment (Child-Pugh A - a score of 5 to 6) · Group 3 (N 6 to 8) – Moderate hepatic impairment (Child-Pugh B a score of 7 to 9) · Group 4 (N 6 to 8) – Severe hepatic impairment (Child-Pugh C a score of 10 to 15) Healthy volunteers with normal hepatic function.

VersionLevelCodeTermSystem organ class
22.1 LLT 10052254 Hepatic impairment 10019805

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sagimet Biosciences Inc.

Sponsor organisation
Sagimet Biosciences Inc.
Address
155 Bovet Road Suite 303
City
San Mateo
Postcode
94402-3135
Country
United States

Scientific contact point

Organisation
Sagimet Biosciences Inc.
Contact name
Eduardo Bruno Martins

Public contact point

Organisation
Sagimet Biosciences Inc.
Contact name
Eduardo Bruno Martins

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ended 16 1
Rest of world
United States
32

Investigational sites

Hungary

1 site · Ended
CRU Hungary Kft.
Early Phase Unit, Semmelweis Ter 1, 2143, Kistarcsa

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2023-09-21 2023-12-18 2023-09-21 2023-12-18

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-05 Hungary Acceptable
2023-08-21
2023-08-24